Transcutaneous vagus nerve stimulation for refractory epilepsy: a randomized controlled trial

Area of Science:

• Neurology
• Medical Devices
• Epilepsy Research

Background:

• Refractory epilepsy presents a significant challenge in patient management.
• Limited treatment options exist for patients with drug-resistant epilepsy.
• Vagus nerve stimulation is an established therapy, but invasive methods carry risks.

Purpose of the Study:

• To evaluate the safety and efficacy of transcutaneous auricular vagus nerve stimulation (ta-VNS) in patients with refractory epilepsy.
• To compare the effectiveness of ta-VNS against a sham control (transcutaneous auricular non-vagus nerve stimulation, tn-VNS).
• To assess the impact of ta-VNS on seizure frequency, EEG, and quality of life.

Main Methods:

• A randomized controlled trial involving 144 patients with refractory epilepsy.
• Patients were assigned to either ta-VNS or tn-VNS groups for 24 weeks of treatment, twice daily.
• Seizure frequency and Modified Engel Scale were assessed at 8, 16, and 24 weeks. Patients in the control group switched to ta-VNS after 8 weeks.

Main Results:

• After 8 weeks, ta-VNS showed a significantly higher seizure reduction (41.0%) compared to tn-VNS (27.5%).
• Average seizure frequency reduction was 42.6% for ta-VNS versus 11.5% for tn-VNS after 8 weeks (P<0.05).
• After 24 weeks, ta-VNS achieved a 47.7% reduction, with the tn-VNS group reaching 47.5% after an additional 16 weeks of ta-VNS treatment. Significant improvements in EEG and quality of life were also observed.

Conclusions:

• Transcutaneous auricular vagus nerve stimulation (ta-VNS) is a safe and effective treatment for reducing seizure frequency in refractory epilepsy.
• ta-VNS demonstrates significant improvements in electroencephalograph (EEG) readings and patients' quality of life.
• The non-invasive, economic, and widely applicable nature of ta-VNS suggests its potential as a valuable therapeutic option for refractory epilepsy.